Can Furosemide Be Used in Pregnancy?
Furosemide can be used during pregnancy when the potential maternal benefit justifies the potential fetal risk, but it should not be used routinely and is reserved for specific indications such as pulmonary edema or heart failure with severe congestion. 1
FDA Classification and Animal Data
The FDA classifies furosemide as Category C, meaning animal studies have shown adverse effects but there are no adequate controlled studies in pregnant women 1. Critical animal data includes:
- Maternal deaths and abortions occurred in rabbits at doses as low as 2 times the maximum human dose (25 mg/kg)
- At 4 times the maximum human dose (50 mg/kg), maternal deaths and abortions occurred between days 12-17 of gestation
- At 8 times the maximum dose (100 mg/kg), no pregnant rabbits survived
- Increased incidence of fetal hydronephrosis (distention of renal pelvis and ureters) was observed in surviving fetuses 1
Guideline-Based Indications
When Furosemide IS Indicated:
Pre-eclampsia with pulmonary edema: Nitroglycerine (glyceryl trinitrate) is the drug of choice, given as IV infusion starting at 5 mcg/min and gradually increased every 3-5 minutes to a maximum of 100 mcg/min 2, 3. Furosemide is not specifically mentioned as first-line for this indication in the most recent guidelines.
Heart failure during pregnancy: When mild heart failure occurs without fetal distress, pregnancy should continue with heart failure management, which may include diuretics 2. The decision requires a multidisciplinary team assessment of maternal and fetal condition.
When Furosemide is NOT Indicated:
- Routine management of hypertension in pregnancy - other agents (labetalol, methyldopa, nifedipine) are preferred 2, 3
- Routine management of pre-eclampsia without pulmonary edema - not recommended 2, 3
- Physiologic edema of pregnancy - this is normal and does not require treatment
Recent Clinical Evidence
The 2024 ROPAC registry study (largest dataset with 5,739 pregnancies) provides reassuring data 4:
- Diuretics were used in 6.7% of pregnancies (86% furosemide)
- No significant association with congenital anomalies when used in first trimester (OR 1.3,95% CI 0.7-2.6)
- No significant association with small for gestational age infants (OR 1.4,95% CI 1.0-1.9)
- Most commonly used in women with heart failure, cardiomyopathy, or valvular disease
A 2023 systematic review and meta-analysis showed 5:
- Antepartum use lowered diastolic BP (mean difference -17.73 mmHg) and cardiac output
- Postpartum use reduced need for additional antihypertensives (RR 0.69)
- Insufficient evidence to suggest clear benefit for routine use
Clinical Algorithm for Decision-Making
Step 1: Identify the indication
- Pulmonary edema with pre-eclampsia → Consider nitroglycerine first 2, 3
- Heart failure with severe congestion → Furosemide may be appropriate 2
- Hypertension alone → Use labetalol, methyldopa, or nifedipine instead 2, 3
Step 2: Assess gestational age
- First trimester: Avoid if possible due to theoretical teratogenic concerns from animal data
- Second/third trimester: Can use if maternal indication is compelling
Step 3: Weigh maternal vs. fetal risk
- Life-threatening maternal condition (pulmonary edema, severe heart failure) → Benefits likely outweigh risks
- Non-life-threatening condition → Choose alternative agents
Step 4: If furosemide is used
- Monitor fetal growth closely (potential for higher birth weights noted in FDA label) 1
- Use lowest effective dose
- Monitor maternal electrolytes and renal function
- Consider fetal ultrasound monitoring
Critical Caveats
⚠️ The FDA label explicitly states: "Furosemide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus" 1
⚠️ Treatment during pregnancy requires monitoring of fetal growth because of potential for higher birth weights 1
⚠️ Furosemide appears in breast milk and may inhibit lactation, requiring caution in nursing mothers 1
⚠️ The theoretical concern about reducing placental perfusion through volume depletion has not been substantiated in clinical studies 6, but prudent use remains warranted
Postpartum Use
Furosemide has stronger evidence for postpartum use in women with preeclampsia 7:
- A 2025 RCT showed 40 mg/day oral furosemide for 5 days postpartum reduced mean systolic and diastolic BP
- Reduced time to blood pressure control (P=0.01)
- Fewer severe hypertensive episodes
- This represents a safer time to use furosemide with clear maternal benefit